Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
Open Access
- 25 February 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin
- Vol. 48 (3) , 609-619
Abstract
This is a placebo-controlled multi-national trial of roluperidone, a compound with antagonist properties for 5-HT2A, sigma2, and α1A-adrenergic receptors, targeting negative symptoms in patients with schizophrenia. This trial follows a previous trial that demonstrated roluperidone superiority over placebo in a similar patient population. Roluperidone 32 mg/day, roluperidone 64 mg/day, or placebo was administered for 12 weeks to 513 patients with schizophrenia with moderate to severe negative symptoms. The primary endpoint was the PANSS-derived Negative Symptom Factor Score (NSFS) and the key secondary endpoint was Personal and Social Performance scale (PSP) total score. NSFS scores were lower (improved) for roluperidone 64 mg compared to placebo and marginally missing statistical significance for the intent-to-treat (ITT) analysis data set (P ≤ .064), but reached nominal significance (P ≤ .044) for the modified-ITT (m-ITT) data set. Changes in PSP total score were statistically significantly better on roluperidone 64 mg compared to placebo for both ITT and m-ITT (P ≤ .021 and P ≤ .017, respectively). Results of this trial confirm the potential of roluperidone as a treatment of negative symptoms and improving everyday functioning in patients with schizophrenia. Study registration: Eudra-CT: 2017-003333-29; NCT03397134.Keywords
This publication has 45 references indexed in Scilit:
- Does treatment of schizophrenia with antipsychotic medications eliminate or reduce psychosis? A 20-year multi-follow-up studyPsychological Medicine, 2014
- A selective sigma‐2 receptor ligand antagonizes cocaine‐induced hyperlocomotion in miceSynapse, 2013
- Antipsychotic Medication During the Critical Period Following Remission From First-Episode PsychosisJAMA Psychiatry, 2013
- Recovery in Remitted First-Episode Psychosis at 7 Years of Follow-up of an Early Dose Reduction/Discontinuation or Maintenance Treatment StrategyJAMA Psychiatry, 2013
- A Role for Sigma Receptors in Stimulant Self Administration and AddictionPharmaceuticals, 2011
- Toward the Next Generation of Negative Symptom Assessments: The Collaboration to Advance Negative Symptom Assessment in SchizophreniaSchizophrenia Bulletin, 2010
- Prevalence of Negative Symptoms in Outpatients With Schizophrenia Spectrum Disorders Treated With Antipsychotics in Routine Clinical PracticeThe Journal of Clinical Psychiatry, 2009
- Social functioning as an outcome measure in schizophrenia studiesActa Psychiatrica Scandinavica, 2007
- Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group*European Psychiatry, 2000
- Empirical Assessment of the Factorial Structure of Clinical Symptoms in SchizophreniaPsychopathology, 1997